Skip to main content


A new study has discovered a powerful force that is now driving evolution on Earth.

In a lab investigation, Johnson & Johnson's COVID vaccination provided essentially little antibody protection against the Omicron strain.

Concerns concerning J&J's effectiveness against Omicron have been raised in a South African study.

In test tube studies, there is almost little antibody response to the variation.
According to the CDC, Omicron accounts for 13% of cases in New York and New Jersey.

Officials anticipate a punishing wave of cases as early as January. Experts now recommend a booster shot to improve Omicron protection.

According to a new study, the COVID-19 vaccination from Johnson & Johnson produced virtually no antibody response to the Omicron version.

Penny Moore, a South African virologist, discovered that in those who had the J&J shot, a critical marker of antibody levels dropped from 303 against the original strain to undetectable levels against Omicron.

The antibody measure, known as geometric mean titers, plummeted from 1,419 against the original coronavirus strain to 80 against Omicron among individuals who received the Pfizer shot.

In a presentation on Tuesday, she said, "Omicron does certainly exhibit considerable immunological escape from antibodies." 'I believe the issue is much more concerning for the J&J vaccination, as we found no evidence of neutralisation in our assay.'

According to data from several state reporting authorities, confirmed US Omicron case numbers had risen to 241 as of Wednesday, up 27% from 189 the day before.

However, CDC experts have warned that the true scope of Omicron infection is significantly greater, with the variety currently accounting for about 3% of all US COVID cases, or up to 13% in New York and New Jersey.

Meanwhile, Cornell University in upstate New York is suspected of being the site of the largest Omicron outbreak in the United States to date, with over 900 cases, almost all of which specialists believe were caused by Omicron.

The J&J study, which used human blood plasma and was conducted in a test tube, has yet to be published.

Other immune responses to Omicron, such as from strong T cells, are not ruled out in patients who have received the J&J vaccine.

Johnson & Johnson did not immediately react to a request for comment, but linked to a previous statement in which the company stated that it is closely studying Omicron and is working on a vaccine for it.

To reduce COVID-19 hospitalizations and deaths, the novel Omicron version emphasises the significance of ongoing surveillance, testing, and immunisation.

Dr. Anthony Fauci, the nation's top infectious disease expert, has encouraged anybody who is eligible to obtain an Omicron vaccination booster, claiming that it provides superior protection.

Boosters are recommended for adults two months after having the J&J shot and six months after the final course of Pfizer and Moderna, according to the Centers for Disease Control and Prevention.

The J&J vaccine was given to roughly 17 million Americans, accounting for fewer than 10% of all vaccinations in the country, while the Pfizer and Moderna vaccines are significantly more widely used.

According to the Centers for Disease Control and Prevention (CDC), 202 million Americans, or 61% of the population, are completely immunised. A booster dose was given to 27% of individuals who were fully immunised.

Omicron appears to be spreading even faster than previous coronavirus variations, with the CDC estimating that it currently accounts for 3% of all new cases across the US.

Surprisingly, Omicron is now thought to account for 13% of new cases in New York and New Jersey, where infection rates are rapidly rising.

Only 241 Omicron instances have been confirmed through DNA sequencing across 37 states, but the true number is almost certainly much higher.

Officials from the Centers for Disease Control and Prevention convened a secret phone briefing with top public health experts on Tuesday, warning that Omicron could bring a major wave of infections and hospitalizations to the United States as early as January.

The worst-case scenario, according to the briefing, is a 'triple whammy,' in which Omicron rises with the Delta variant and the flu to overrun hospitals by next month.

A lesser Omicron surge in the spring is the second scenario. Which possibility is most likely is unknown.

They're debating the material at the highest levels right now, one government health official aware with the briefing told the Post, and thinking about how to persuade the public to grasp what the scenarios mean. It appears to be a difficult situation.

One of Moderna's managers has cautioned that if Omicron and Delta infect someone at the same moment, a new super-variant could emerge.

In most situations, only one mutant strain is involved in a Covid infection, but in exceedingly rare cases, two mutant strains can strike at the same time.

If both of these viruses infect the same cell, they could be able to swap DNA and merge to form a new virus.

This was made more likely by the large number of Delta and Omicron cases now circulating in the United Kingdom.

It's 'absolutely' feasible that they'll switch genes and cause a more harmful variation to emerge.

As the variation wreaks havoc in Europe, American officials are prepared for an Omicron wave.

The ultra-transmissible strain is already prevalent in London, with dismal projections estimating that at least 200,000 individuals in the UK may contract it every day.

The United Kingdom had the highest day number of lab-confirmed coronavirus cases since the outbreak began on Wednesday.

As of 9 a.m. on Wednesday, there had been 78,610 new cases reported, setting a pandemic record.

Boris Johnson, the British Prime Minister, will attend a press conference on Wednesday evening as he faces mounting pressure from his own aides to panic over new limits, with concerns that the country's health system is in'serious jeopardy.'

Meanwhile, as Europe confronts a new wave of diseases and hospital admissions, Dutch elementary schools will close early for the Christmas break.

63,405 new coronavirus cases were reported in France on Tuesday, the highest daily number since April, despite the fact that more than 77 percent of the country's population had received at least one vaccination.

According to a Johns Hopkins University tracker, the United States is the country hardest afflicted by the pandemic, with 800,000 known COVID-19 deaths as of Tuesday.

Omicron was discovered by South Africa and reported to the WHO on November 24. It has a large number of mutations, which has raised alarm since its discovery.

Early evidence suggests it may be vaccine resistant and more transmissible than the Delta form, which was first discovered in India and accounts for the majority of coronavirus cases worldwide.

The strain had been reported in 77 countries, according to WHO chief Tedros Adhanom Ghebreyesus, and had 'probably' spread undetected to most countries 'at a rate we have not seen with any previous variety'.

However, a promising study from South Africa was released this week.

The study, conducted by Discovery Health, discovered that occurrences of the strain are modest and unlikely to result in hospitalisation or death. According to the study, people infected with Omicron are 20% less likely to be hospitalised than those infected with the Delta form.

The study indicates, however, that the variety spreads more quicker than earlier viral strains and can bypass protection afforded by the Pfizer vaccine, which is the most widely used in the United States.

Even though hospitalisation rates are low, the variation could put a pressure on the healthcare system if large numbers of people become ill.

A post-Thanksgiving storm is already pounding the Northeastern United States, and upcoming Christmas celebrations threaten to accelerate the spread.

The worst-affected state is Connecticut, where cases have nearly tripled in the last two weeks. Every day, almost 71 out of every 100,000 people in the state test positive for the virus.

Nearby Maine (which has had a 168% surge in cases in the last two weeks), Delaware (93%), Rhode Island (91%), New Jersey (90%), and Massachusetts (88%) are also among the top states.

Over the last two weeks, the number of new cases in Alabama has doubled, indicating that the recent winter surge is starting to take hold in the south as well.

A vast majority of these new cases are still of the Delta variant, though, as the strain that has dominated much of the second half of 2021 still makes up 97 per cent of sequenced cases in the U.S.